CytomX Therapeutics Inc
(NAS:CTMX)
$
1.02
-0.12 (-10.53%)
Market Cap: 79.82 Mil
Enterprise Value: -17.78 Mil
PE Ratio: 6.00
PB Ratio: 0
GF Score: 57/100 CytomX Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020 / 08:40PM GMT
Release Date Price:
$7.93
(-1.49%)
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD
Great. Good afternoon, everybody. Thank you for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. Very pleased to be hosting CytomX this afternoon as part of our virtual conference. Joining us from the company is Sean McCarthy, who's President, CEO and Chairman.
Sean, thank you very much for joining us. Really appreciate your time today.
Sean A. McCarthy
CytomX Therapeutics, Inc. - Chairman, CEO & President
Great. Thanks, Terence. Absolute pleasure to be here.
Questions & Answers
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD
Maybe just to start, I thought you could set the stage and give a little bit of an overview of the company and the strategy for those on the webcast that maybe aren't as familiar with what you guys have been working on over the last several years.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot